GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (NAS:PRPO) » Definitions » Gross Margin %

Precipio (Precipio) Gross Margin % : 46.50% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Precipio Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Precipio's Gross Profit for the three months ended in Dec. 2023 was $2.01 Mil. Precipio's Revenue for the three months ended in Dec. 2023 was $4.33 Mil. Therefore, Precipio's Gross Margin % for the quarter that ended in Dec. 2023 was 46.50%.


The historical rank and industry rank for Precipio's Gross Margin % or its related term are showing as below:

PRPO' s Gross Margin % Range Over the Past 10 Years
Min: -75.4   Med: 17.92   Max: 43.7
Current: 39.6


During the past 13 years, the highest Gross Margin % of Precipio was 43.70%. The lowest was -75.40%. And the median was 17.92%.

PRPO's Gross Margin % is ranked worse than
58.41% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: 45.595 vs PRPO: 39.60

Precipio had a gross margin of 46.50% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Precipio was 42.80% per year.


Precipio Gross Margin % Historical Data

The historical data trend for Precipio's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precipio Gross Margin % Chart

Precipio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 18.88 27.03 26.67 39.60

Precipio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.01 26.59 38.81 41.72 46.50

Competitive Comparison of Precipio's Gross Margin %

For the Diagnostics & Research subindustry, Precipio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precipio's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Precipio's Gross Margin % falls into.



Precipio Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Precipio's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=6 / 15.197
=(Revenue - Cost of Goods Sold) / Revenue
=(15.197 - 9.179) / 15.197
=39.60 %

Precipio's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=2 / 4.329
=(Revenue - Cost of Goods Sold) / Revenue
=(4.329 - 2.316) / 4.329
=46.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Precipio  (NAS:PRPO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Precipio had a gross margin of 46.50% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Precipio Gross Margin % Related Terms

Thank you for viewing the detailed overview of Precipio's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Precipio (Precipio) Business Description

Traded in Other Exchanges
N/A
Address
4 Science Park, New Haven, CT, USA, 06511
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings.
Executives
Richard A Sandberg director 330 NEVEDA STREET, NEWTON MA 02460-1458
Ahmed Zaki Sabet officer: Chief Operations Officer 33 ANDYS DR, EAST HAVEN CT 06512
Ilan Danieli director, officer: Chief Executive Officer 14707 CALIFORNIA STREET, SUITE 5, OMAHA NE 68154
Matthew Gage officer: Chief Financial Officer 56 STAGECOACH CIRCLE, MILFORD CT 06460
David Seth Cohen director, 10 percent owner C/O STANDARD OIL, 299 BISHOP AVENUE, BRIDGEPORT CT 06610
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Kathleen Laporte director
Robert Patzig director THE GOVERNOR TYLER, 1881 GROVE AVENUE, RADFORD VA 24141
Michael A Luther director 21 CORPORATE CIRCLE, ALBANY NY 12203
Jeffrey Cossman director C/O PRECIPIO INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Carl Iberger officer: Chief Financial Officer C/O PRECIPIO, INC., 12325 EMMET STREET, OMAHA NE 68164
Douglas Fisher director 587 PATROL RD, WOODSIDE CA 94062
Mark Rimer director, 10 percent owner C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511